Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ionis Antisense Platform Safety Questioned After Thrombocytopenia Seen In Studies

Executive Summary

GSK halts plans for Phase III study of antisense candidate in FAC due to FDA clinical hold for findings of reduced platelet counts in another Phase III trial; Ionis reveals similar findings in Phase III study of another antisense compound.

Advertisement

Related Content

Stockwatch: Alnylam Helps Nucleic Acid Drugs Degrade
Alnylam Ends Revusiran In Phase III, But Was Failure Due To Safety Or Efficacy?
Stockwatch: A Week Of Dashed Expectations
Ionis Sells Kynamro To Kastle After Regaining Rights From Genzyme

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register